{'fraction_non_alphanumeric': 0.04144527098831031, 'fraction_numerical': 0.028692879914984058, 'mean_word_length': 5.5874125874125875, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 2, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[A Case of Long-Term Survival of a Patient with Cholangiocarcinoma and Liver Metastatic Recurrence Who Responded to Gemcitabine plus Cisplatin Therapy].

A 65-year-old woman was diagnosed with cholangiocarcinoma and underwent hepato-pancreatoduodenectomy. The pathological diagnosis was Bpd, circ, papillary-infiltrating type, 51×47×7mm, tub2>tub1>por1, T2, ly1, v1, ne1, pN0, pDM0, pHM0, pEM0, pPV0, pA0, R0, pStageⅠ. She received adjuvant chemotherapy with S-1, which was changed to gemcitabine plus cisplatin therapy(GC therapy)when hepatic recurrence and lymph node metastasis were identified 3 months postoperatively. The hepatic recurrence disappeared, and the lymph node metastasis was reduced after the patient completed 27 courses of GC therapy. We discontinued GC therapy as no recurrence had been observed for a long time. The patient remains well without any evidence of cancer recurrence for more than 48 months postoperatively.